AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18203246 — intervention group
Group type: EXPERIMENTAL
Intervention: PCS Knowledge Influence
Number of subjects: 286
Study 15632666 — intervention group
Group type: EXPERIMENTAL
Intervention: Low progestin oral contraceptives
Number of subjects: 14
Study 15632666 — intervention group
Group type: EXPERIMENTAL
Intervention: High progestin oral contraceptives
Number of subjects: 14
Study 15632666 — intervention group
Group type: COMPARATOR
Intervention: Active pill phase
Number of subjects: 14
Study 15632666 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill phase
Number of subjects: 14
Study 14581245 — intervention group
Group type: EXPERIMENTAL
Intervention: INH + OHA group (n = 32)
Number of subjects: 68
Study 14581245 — intervention group
Group type: COMPARATOR
Intervention: OHA group (n = 36)
Number of subjects: 68
Study 14581245 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 10888689 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based telephone system (autodialer)
Number of subjects: 0
Study 10888689 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual postcard system (mail)
Number of subjects: 0
Study 10888689 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8757408 — intervention group
Group type: EXPERIMENTAL
Intervention: CO/SL (Carbon Monoxide at Sea Level)
Number of subjects: 17
Study 8757408 — intervention group
Group type: EXPERIMENTAL
Intervention: CA/HA (Clean Air at High Altitude)
Number of subjects: 17
Study 8757408 — intervention group
Group type: EXPERIMENTAL
Intervention: CO/HA (Carbon Monoxide at High Altitude)
Number of subjects: 17
Study 8757408 — intervention group
Group type: COMPARATOR
Intervention: CA/SL (Clean Air at Sea Level)
Number of subjects: 17
Study 1329479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 5‐20 mg once daily
Number of subjects: 217
Study 1329479 — intervention group
Group type: COMPARATOR
Intervention: Digoxin 0.125‐0.375 mg once daily
Number of subjects: 217
Study 3933397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (28% carbohydrate calories, 55% fat calories)
Number of subjects: 0
Study 3933397 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate diet
Number of subjects: 0
Study 3933397 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet
Number of subjects: 0
Study 28854500 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity laser therapy (HILT) combined with spinal decompression system (SDS)
Number of subjects: 63
Study 28854500 — intervention group
Group type: COMPARATOR
Intervention: Spinal decompression system (SDS) alone
Number of subjects: 63
Study 26862829 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg RBP-7000
Number of subjects: 0
Study 26862829 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg RBP-7000
Number of subjects: 0
Study 26862829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24829213 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles vaccination (MV) in the presence of maternal antibody
Number of subjects: 0
Study 24829213 — intervention group
Group type: COMPARATOR
Intervention: Measles vaccination (MV) without maternal antibody
Number of subjects: 0
Study 24829213 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of measles vaccination (MV) with maternal antibody
Number of subjects: 0
Study 23184299 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile geriatric consultant service (GECO)
Number of subjects: 100
Study 23184299 — intervention group
Group type: COMPARATOR
Intervention: General practitioners' medical attendance (control)
Number of subjects: 100
Study 20141454 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session Motivational Interviewing (MI)
Number of subjects: 35
Study 20141454 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 35
Study 18043421 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment and physical disability
Number of subjects: 391
Study 18043421 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical, visual, and psychological factors
Number of subjects: 391
Study 18043421 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual disability
Number of subjects: 391
Study 16263359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy (IRT) using tungsten (188W) at doses of 18, 22, or 25 Gy
Number of subjects: 30
Study 16263359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy (IRT) using tungsten (188W)
Number of subjects: 30
Study 16263359 — intervention group
Group type: COMPARATOR
Intervention: Comparison with the original WRIST radiation cohort using 192Iridium source
Number of subjects: 30
Study 16263359 — intervention group
Group type: COMPARATOR
Intervention: Comparison with the WRIST placebo cohort
Number of subjects: 30
Study 12242074 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab for 24 h, 48 h
Number of subjects: 7800
Study 10486790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternal skin conductance monitor
Number of subjects: 24
Study 10486790 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective reporting of hot flashes
Number of subjects: 24
Study 10486790 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin conductance monitoring during waking hours
Number of subjects: 24
Study 8758159 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam with alfentanil
Number of subjects: 0
Study 8758159 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil alone
Number of subjects: 0
Study 1949258 — intervention group
Group type: EXPERIMENTAL
Intervention: LongoVital (LV)
Number of subjects: 31
Study 6524990 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria prophylaxis
Number of subjects: 0
Study 6524990 — intervention group
Group type: COMPARATOR
Intervention: No malaria prophylaxis (Control)
Number of subjects: 0
Study 31335582 — intervention group
Group type: EXPERIMENTAL
Intervention: Teens with ADHD
Number of subjects: 0
Study 31335582 — intervention group
Group type: EXPERIMENTAL
Intervention: Teens with TSF
Number of subjects: 0
Study 31335582 — intervention group
Group type: COMPARATOR
Intervention: Typically Developing (TD) teens
Number of subjects: 0
Study 30109908 — intervention group
Group type: EXPERIMENTAL
Intervention: B-GOS® (2.75 g/d)
Number of subjects: 83
Study 30109908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 27001136 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy according to the Utrecht School (MTU)
Number of subjects: 181
Study 27001136 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (PT)
Number of subjects: 181
Study 23232844 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol plus NAC
Number of subjects: 311
Study 23232844 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 311
Study 21585221 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapeutic follow-up programme (PTP)
Number of subjects: 732
Study 19384757 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (Tissucol Duo, Baxter AG, Vienna, Austria)
Number of subjects: 17
Study 19384757 — intervention group
Group type: COMPARATOR
Intervention: Suture (7‐0 silk)
Number of subjects: 17
Study 17061673 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-group chinolone
Number of subjects: 18
Study 17061673 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin/Ceftriaxone
Number of subjects: 18
Study 17061673 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 18
Study 15503071 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of resources (cognition, health, social network) in young individuals
Number of subjects: 0
Study 15503071 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of resources (cognition, health, social network) in old individuals
Number of subjects: 0
Study 15503071 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource status in both age groups
Number of subjects: 0
Study 15503071 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource loss in young individuals
Number of subjects: 0
Study 15503071 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource loss in old individuals
Number of subjects: 0
Study 10833739 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (Prozac) with information about weight loss side effects
Number of subjects: 60
Study 10833739 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (Tofranil) with information about weight gain side effects
Number of subjects: 60
Study 10833739 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (Prozac) without information about weight-related side effects
Number of subjects: 60
Study 10833739 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (Tofranil) without information about weight-related side effects
Number of subjects: 60
Study 9284876 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-record rating
Number of subjects: 78
Study 9284876 — intervention group
Group type: COMPARATOR
Intervention: Fat-gram counting
Number of subjects: 78
Study 8335047 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 1 gram dose of ceftazidime with the induction of anaesthesia
Number of subjects: 764
Study 8335047 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g daily ceftazidime from induction of anaesthesia until removal of the urethral catheter (but ≤ 5 days)
Number of subjects: 764
Study 8335047 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 764
Study 8335047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-treated groups (both single-dose and multidose)
Number of subjects: 764
Study 3567048 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion at rates of 6.1 mg min‐1 and above
Number of subjects: 6
Study 3567048 — intervention group
Group type: COMPARATOR
Intervention: Inosine infusion at dose rates up to 16.8 mg min‐1
Number of subjects: 6
Study 29455044 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% perioperative inspiratory oxygen fraction
Number of subjects: 1400
Study 29455044 — intervention group
Group type: COMPARATOR
Intervention: 30% perioperative inspiratory oxygen fraction
Number of subjects: 1400
Study 27746224 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Number of subjects: 1761
Study 27746224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1761
Study 24516018 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 291
Study 21979801 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan (100 mg/day)
Number of subjects: 22
Study 21979801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 19733875 — intervention group
Group type: EXPERIMENTAL
Intervention: Argemone mexicana decoction (AM)
Number of subjects: 301
Study 19733875 — intervention group
Group type: COMPARATOR
Intervention: artesunate-amodiaquine (ACT)
Number of subjects: 301
Study 19733875 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AM and ACT
Number of subjects: 301
Study 18404697 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 40
Study 18404697 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 40
Study 19279966 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF/KNO3 dentifrice (Sensodyne ProNamel)
Number of subjects: 25
Study 19279966 — intervention group
Group type: COMPARATOR
Intervention: SnF2/SHMP dentifrice (blend-a-med EXPERT GUMS PROTECTION)
Number of subjects: 25
Study 15051614 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (4.9 g/d)
Number of subjects: 42
Study 15051614 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (4.7 g/d)
Number of subjects: 42
Study 15051614 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 42
Study 12153647 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional care plus peer support
Number of subjects: 256
Study 12153647 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 256
Study 9772929 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti Gp IIb‐IIIa (Reopro chimeric antibody, Abciximab®)
Number of subjects: 0
Study 9772929 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin and its derivatives
Number of subjects: 0
Study 9772929 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins
Number of subjects: 0
Study 8165068 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic medicine
Number of subjects: 81
Study 8165068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 2905500 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam (0.03 mg/kg IV) + ZK 93 426 (0.04 mg/kg IV)
Number of subjects: 0
Study 2905500 — intervention group
Group type: COMPARATOR
Intervention: Lormetazepam (0.03 mg/kg IV)
Number of subjects: 0
Study 2905500 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 93 426 (0.04 mg/kg IV)
Number of subjects: 0
Study 2905500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11551875 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 303
Study 11551875 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 303
Study 30574801 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Number of subjects: 56
Study 30192446 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation via telehealth
Number of subjects: 241
Study 30192446 — intervention group
Group type: COMPARATOR
Intervention: Behavioral activation in-person
Number of subjects: 241
Study 26372539 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD‐9‐CM code for dermatitis due to drug (693.0)
Number of subjects: 1634
Study 26372539 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD‐9‐CM code for adverse reaction to drug (995.2)
Number of subjects: 1634
Study 26372539 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD‐9‐CM code for anaphylaxis (995.0)
Number of subjects: 1634
Study 26372539 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD‐9‐CM code and E code combination
Number of subjects: 1634
Study 26372539 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall allergic drug reactions
Number of subjects: 1634
Study 26372539 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of allergic drug reactions
Number of subjects: 1634
Study 24643895 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 209
Study 24643895 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 209
Study 23283449 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniform multidrug therapy (U‐MDT) for leprosy
Number of subjects: 858
Study 23283449 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment regimen for leprosy
Number of subjects: 858
Study 20819222 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative implementation strategy including a computerized decision support system (BOS)
Number of subjects: 472
Study 20819222 — intervention group
Group type: COMPARATOR
Intervention: Common strategy of professional audit and feedback
Number of subjects: 472
Study 17668537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valacyclovir suppressive therapy (1 g once daily for 6 months)
Number of subjects: 0
Study 17668537 — intervention group
Group type: COMPARATOR
Intervention: Oral valacyclovir episodic therapy (two 2-g doses separated by 12 hours at first sign of prodrome for 6 months)
Number of subjects: 0
Study 16265352 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with chemotherapy (weekly 5-fluorouracil and leucovorin 500 and 20 mg m(‐2), respectively)
Number of subjects: 168
Study 16265352 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with chemotherapy (daily x 5 Mayo Clinic schedule 425 and 20 mg m(‐2), respectively)
Number of subjects: 168
Study 16265352 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with chemotherapy (Mayo schedule)
Number of subjects: 168
Study 16265352 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (at onset of predefined symptoms)
Number of subjects: 168
Study 16265352 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with chemotherapy
Number of subjects: 168
Study 16265352 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 168
Study 12075639 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) ointment
Number of subjects: 80
Study 12075639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10426172 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 137
Study 10426172 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula
Number of subjects: 137
Study 10426172 — intervention group
Group type: COMPARATOR
Intervention: Intervention children (previously formula-fed)
Number of subjects: 137
Study 10426172 — intervention group
Group type: COMPARATOR
Intervention: Control children (previously formula-fed)
Number of subjects: 137
Study 10426172 — intervention group
Group type: COMPARATOR
Intervention: Intervention children (previously breastfed)
Number of subjects: 137
Study 10426172 — intervention group
Group type: COMPARATOR
Intervention: Control children (previously breastfed)
Number of subjects: 137
Study 8672820 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% lipid emulsion amphotericin B (1 mg/mL)
Number of subjects: 20
Study 8672820 — intervention group
Group type: COMPARATOR
Intervention: Conventional amphotericin B (0.1 mg/mL) in dextrose 5% solution
Number of subjects: 20
Study 2223742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate intake (0.83 to 5.20 mmol/d)
Number of subjects: 6
Study 365213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine
Number of subjects: 14
Study 365213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31833259 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) without interval debulking surgery
Number of subjects: 224
Study 31833259 — intervention group
Group type: COMPARATOR
Intervention: Interval debulking surgery (IDS) after NACT
Number of subjects: 224
Study 31453631 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 90
Study 31453631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 28734659 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (VAC)
Number of subjects: 51
Study 28734659 — intervention group
Group type: COMPARATOR
Intervention: Traditional wrap and bandages
Number of subjects: 51
Study 25697236 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 536
Study 25697236 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self‐help
Number of subjects: 536
Study 25697236 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 536
Study 25697236 — intervention group
Group type: COMPARATOR
Intervention: Bibliotherapy
Number of subjects: 536
Study 24634631 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 20
Study 24634631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22011907 — intervention group
Group type: EXPERIMENTAL
Intervention: briakinumab (200 mg at weeks 0 and 4 and 100 mg at week 8)
Number of subjects: 76
Study 22011907 — intervention group
Group type: EXPERIMENTAL
Intervention: briakinumab 100 mg every 4 weeks (q4-wk)
Number of subjects: 76
Study 22011907 — intervention group
Group type: EXPERIMENTAL
Intervention: briakinumab 100 mg every 12 weeks (q12-wk)
Number of subjects: 76
Study 22011907 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 76
Study 19576353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 19576353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17180286 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 100
Study 15128701 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 15186523 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccine
Number of subjects: 80
Study 15186523 — intervention group
Group type: COMPARATOR
Intervention: Not vaccinated (control group)
Number of subjects: 80
Study 11210884 — intervention group
Group type: COMPARATOR
Intervention: Parenteral piperacillin/tazobactam (3.375 g every 6 hours for 48 h)
Number of subjects: 62
Study 11210884 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral piperacillin/tazobactam plus topical piperacillin/tazobactam administered as a mouthwash immediately before surgery and once a day for 2 days postoperatively
Number of subjects: 62
Study 9467534 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-677 25 mg
Number of subjects: 8
Study 9467534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7948820 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha-2a therapy
Number of subjects: 0
Study 7948820 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 7948820 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver biopsies from patients with HC/HNANB infection
Number of subjects: 0
Study 3283625 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IFN alpha-2c (1.2 x 10 IU/m x 28 days s.c. or lower)
Number of subjects: 84
Study 3283625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile IFN on 7 consecutive days within a 28-day period
Number of subjects: 84
Study 3283625 — intervention group
Group type: COMPARATOR
Intervention: Daily IFN
Number of subjects: 84
Study 30188590 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL sucrose (25% in South Africa, 24% in Norway)
Number of subjects: 53
Study 30188590 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mL sucrose (25% in South Africa, 24% in Norway)
Number of subjects: 53
Study 30188590 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL sucrose
Number of subjects: 53
Study 30188590 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mL sucrose
Number of subjects: 53
Study 28142387 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment
Number of subjects: 85